

Deepa Rangachari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2255802/publications.pdf>

Version: 2024-02-01

48
papers

1,759
citations

361413

20
h-index

289244

40
g-index

48
all docs

48
docs citations

48
times ranked

3015
citing authors

#	ARTICLE	IF	CITATIONS
1	Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform. JCO Oncology Practice, 2022, 18, e36-e46.	2.9	6
2	Oncology Fellows' Clinical Discussions, Perceived Knowledge, and Formal Training Regarding Medical Cannabis Use: A National Survey Study. JCO Oncology Practice, 2022, 18, e1762-e1776.	2.9	5
3	Trastuzumab Deruxtecan in Non-“Small-Cell Lung Cancer. New England Journal of Medicine, 2022, 386, 1769-1771.	27.0	3
4	Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-“small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e379-e389.	2.6	13
5	The rapidly evolving landscape of biomarker testing in non-“small cell lung cancer. Cancer Cytopathology, 2021, 129, 179-181.	2.4	13
6	Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist, 2021, 26, 281-287.	3.7	15
7	Association of Performance Status With Survival in Patients With Advanced Non-“Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Network Open, 2021, 4, e2037120.	5.9	73
8	EGFR-D770G and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells, 2021, 10, 3561.	4.1	7
9	Twelve tips for teaching oncology to non-oncologists. Medical Teacher, 2020, 42, 987-992.	1.8	0
10	Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis. Clinical Lung Cancer, 2020, 21, e6-e9.	2.6	3
11	Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?. Precision Cancer Medicine, 2020, 3, 17-17.	1.8	14
12	EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 2020, 1, 100051.	1.1	26
13	Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?. , 2020, 8, e000697.		31
14	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer, 2020, 145, 181-185.	2.0	36
15	Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer. JTO Clinical and Research Reports, 2020, 1, 100071.	1.1	11
16	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clinical and Research Reports, 2020, 1, 100074.	1.1	10
17	Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9507-9507.	1.6	26
18	In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer. Translational Cancer Research, 2020, 9, 1311-1318.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e1-e3.	1.1	8
20	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1995-2002.	1.1	58
21	When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?. <i>Journal of Oncology Practice</i> , 2019, 15, 465-473.	2.5	63
22	Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naïve Programmed Death Ligand 1 Positive Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e34-e36.	1.1	1
23	From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2511-2513.	1.6	22
24	Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature. <i>Respiratory Medicine Case Reports</i> , 2019, 27, 100834.	0.4	25
25	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	4.1	51
26	Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 715-722.	2.8	5
27	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. <i>Journal of the American Society of Cytopathology</i> , 2018, 7, 133-141.	0.5	56
28	Tumor biomarker testing in non-small-cell lung cancer: A decade of change. <i>Lung Cancer</i> , 2018, 116, 90-95.	2.0	46
29	Updated Correlation of 22C3-PD-L1 $\geq 50\%$ Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor Resistant Setting. <i>Journal of Thoracic Oncology</i> , 2018, 13, e81-e83.	1.1	0
30	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1037-1042.	1.1	83
31	Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. <i>Cancer Treatment and Research Communications</i> , 2018, 15, 17-20.	1.7	10
32	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 6548-6555.	7.0	49
33	Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. <i>Blood</i> , 2018, 132, 1037-1037.	1.4	1
34	Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. <i>Translational Cancer Research</i> , 2018, 7, S779-S786.	1.0	43
35	Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. <i>Lung Cancer</i> , 2017, 106, 17-21.	2.0	149
36	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3 PD-L1 $\geq 50\%$ Expression in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 878-883.	1.1	109

#	ARTICLE	IF	CITATIONS
37	Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, e175-e177.	1.1	15
38	Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, e349-e356.	2.6	31
39	De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. <i>Lung Cancer</i> , 2017, 114, 108-110.	2.0	9
40	Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2812-2818.	1.4	1
41	Beyond the Sandwich: From Feedback to Clinical Coaching for Residents as Teachers. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 2017, 13, 10627.	1.2	5
42	Rapidly fatal advanced EGFR -mutated lung cancers and the need for rapid tumor genotyping in clinical practice. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 41-43.	1.7	7
43	De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. <i>Lung Cancer</i> , 2016, 99, 17-22.	2.0	16
44	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 113-129.	2.6	125
45	Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. <i>Lung Cancer</i> , 2015, 88, 108-111.	2.0	369
46	De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. <i>Lung Cancer</i> , 2015, 88, 70-73.	2.0	30
47	Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. <i>Clinical Lung Cancer</i> , 2015, 16, e105-e109.	2.6	10
48	Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. <i>Lung Cancer</i> , 2015, 90, 369-374.	2.0	70